Pfizer and Enodia Therapeutics have entered into a research collaboration and licensing deal potentially worth over $500m, focused on discovering and developing sec61 inhibitors. Under the agreement, Enodia Therapeutics will lead the initial discovery phase, identifying and refining small-molecule candidates before advancing them against multiple targets. Once the collaboration phase concludes, Pfizer will assume responsibility for the subsequent stages, including clinical trials, manufacturing, regulatory submissions, and commercial operations.

The financial terms provide for an upfront fee for Enodia Therapeutics, alongside potential payments linked to research, development, and sales milestones. The biotechnology company will also be eligible for tiered royalties based on future net sales. Legal counsel for Enodia Therapeutics during the transaction was provided by founding partner Alexandra Carrel and MCE Carrel Avocats member Thomas Rocco.

The collaboration brings together Enodia Therapeutics’ drug discovery capabilities and Pfizer’s clinical and commercial resources to advance the development of potential medicines targeting disease-associated proteins. The programme is centred on the discovery and development of sec61 inhibitors, using an approach designed to target harmful proteins before they contribute to disease pathology while preserving normal cellular functions.

In 2024, the adoption of AI in chemical R&D accelerated, with major pharmaceutical companies reporting significant improvements in their synthesis workflows. Recent data indicates that AI driven platforms can reduce the time spent on retrosynthetic analysis by up to 80 percent, allowing chemists to focus on more complex challenges. For B2B stakeholders, the business case for these technologies is clear: faster development cycles, higher reaction yields, and a reduction in the consumption of expensive chemical reagents. As the global pharmaceutical market becomes increasingly competitive, the ability to optimize chemical synthesis is a key driver of operational efficiency and innovation.

The Power of Retrosynthetic Analysis

The primary application of machine learning in this field is retrosynthetic analysis, the process of working backward from a target molecule to identify the starting materials and chemical steps needed to produce it. Traditionally, this was a manual process that relied on the expertise and memory of a synthetic chemist. AI optimizing small molecule synthesis paths automates this by analyzing millions of published chemical reactions to suggest potential routes. These models can evaluate thousands of possibilities in a matter of seconds, identifying the most efficient paths based on factors such as cost, yield, and step count.

Retrosynthesis models use deep learning and graph neural networks to understand the relationship between chemical structures and reactivity. By learning from the vast body of chemical literature, these models can suggest innovative reactions that might have been overlooked by human experts. This is particularly valuable for complex molecules where the number of potential synthesis routes is astronomical. Furthermore, AI can predict the outcome of reactions with high accuracy, reducing the need for trial and error in the laboratory. Reports indicate that AI driven reaction prediction can achieve accuracies of over 90 percent for many common transformations.

The integration of these models with high throughput screening and automated laboratory hardware is creating a closed loop system for chemical discovery. In this model, the AI suggests a series of reactions, the automated hardware executes them, and the results are fed back into the model to improve future predictions. This self learning cycle dramatically increases the speed of chemical experimentation, allowing researchers to explore a wider range of chemical space and identify more potent drug candidates in less time.

Optimizing Reaction Yields and Reducing Waste

Beyond identifying synthesis routes, AI is also being used to optimize the conditions of each individual reaction. Factors such as temperature, pressure, solvent choice, and catalyst concentration can all have a significant impact on the yield and purity of the final product. AI optimizing small molecule synthesis paths can analyze experimental data to identify the optimal parameters for a specific reaction. This ‘Bayesian optimization’ approach allows chemists to achieve high yields with fewer experiments, saving both time and resources. Optimizing the chemical path is the first step toward achieving predictive waste reduction in drug production by ensuring that every reaction is as lean and efficient as possible.

The reduction of chemical waste is a major business benefit. In traditional synthesis, low yields and inefficient purification steps lead to the generation of significant quantities of chemical waste. By identifying routes with higher yields and fewer side products, AI helps manufacturers operate more sustainably. This is increasingly important as environmental regulations become stricter and the cost of waste disposal rises. Furthermore, AI can identify greener synthesis routes that use less toxic reagents or renewable starting materials, helping pharmaceutical companies meet their corporate social responsibility goals.

From an operational perspective, optimized reactions are easier to scale up from the laboratory to the production floor. AI models can predict how reaction conditions will translate to larger volumes, reducing the risk of failures during the transition to manufacturing. This is particularly vital for the production of active pharmaceutical ingredients (APIs), where even small improvements in yield can lead to millions of dollars in cost savings. For generic drug manufacturers, where margins are often thin, the ability to optimize production is a critical factor for financial success.

Accelerating the Discovery of Novel Chemical Entities

AI is also playing a key role in the discovery of novel chemical entities (NCEs) by suggesting new molecular structures that have desirable pharmacological properties. Machine learning models can be trained on datasets of known drugs and their biological targets to predict the activity of new molecules. This allows researchers to focus their synthesis efforts on the most promising candidates, reducing the number of molecules that need to be synthesized and tested. AI optimizing small molecule synthesis paths ensures that once a promising molecule is identified, the most efficient route to produce it is already known.

This predictive capability is especially valuable for targeting undruggable proteins, where traditional discovery methods have failed. AI can identify subtle interactions between small molecules and their targets, opening up new opportunities for drug development in areas like neurology and infectious diseases. As the quality and quantity of biological data continue to grow, the power of these models will only increase. We are already seeing the first AI discovered drugs entering clinical trials, a major milestone that demonstrates the potential of this technology to transform the industry.

For B2B investors and analysts, the use of AI in drug discovery and synthesis is a strong indicator of a company’s innovation potential. Companies that can leverage these tools effectively will be able to bring a steady stream of new products to market more efficiently than their competitors. The ability to manage the risks and costs of R&D through predictive analytics is a key factor for long term growth in the pharmaceutical sector.

Addressing Data Quality and Accessibility Challenges

The success of AI in small molecule synthesis depends on the availability of high quality, structured data. However, much of the data in chemistry is currently unstructured, stored in thousands of different journals and internal laboratory notebooks. For machine learning models to learn effectively, this data must be extracted, cleaned, and organized into a format that the computer can understand. This is a significant task that requires the use of advanced natural language processing and data engineering tools.

Data sharing is another hurdle. Many pharmaceutical companies are hesitant to share their internal data due to concerns about intellectual property and competitive advantage. However, the development of robust AI models requires large and diverse datasets. We are seeing the emergence of pre competitive collaborations where companies share anonymized data to build better models for the benefit of the entire industry. Furthermore, the use of federated learning allows models to be trained on data from multiple organizations without the data itself being shared.

Finally, there is the need for a change in mindset among researchers. Some chemists may view AI as a threat to their expertise or as a black box that cannot be trusted. Building trust in these tools requires transparency and clear evidence of their effectiveness. Organizations must invest in training and support to help their staff embrace these new ways of working. The goal is not to replace the chemist but to provide them with a powerful partner that can help them solve complex problems more effectively.

Scaling Small Molecule AI and Retrosynthesis

The discovery and chemical synthesis of small molecule therapies are being rapidly transformed by leading pharmaceutical and biotechnology companies utilizing AI and predictive modeling to optimize reaction paths. Gilead Sciences recently accelerated its pipeline by announcing a strategic collaboration with Genesis Therapeutics to leverage its GEMS AI platform to computationally generate and optimize novel small molecules against complex targets. In the biotech space, Recursion Pharmaceuticals fundamentally shifted the market by entering a definitive agreement to acquire Exscientia, aiming to create a global leader combining end-to-end AI and automated chemistry for small molecule creation.

Computational leader Schrödinger recently expanded its successful collaboration with Eli Lilly, utilizing its advanced AI and physics-based software platform to drive predictive small molecule drug discovery. Evotec also demonstrated the power of AI-integrated R&D by nominating a first-in-class small molecule development candidate for dermatology through an advanced discovery collaboration with Almirall. Finally, Merck KGaA continues to pioneer chemical manufacturing optimization by actively driving the deployment of its SYNTHIA™ Retrosynthesis Software, offering targeted grants to researchers to enhance synthetic planning, evaluate chemical space, and execute highly efficient reaction routes.

The Strategic Outlook for Chemical Manufacturing

The integration of AI into small molecule synthesis is a fundamental shift that will reshape the landscape of chemical manufacturing. The future belongs to the digital chemist who can seamlessly combine experimental expertise with data driven insights. For pharmaceutical companies, the move toward optimized synthesis is a strategic imperative that will drive cost reductions, accelerate innovation, and improve sustainability.

Looking forward, we can expect to see even more integration between AI, robotics, and cloud computing. The creation of autonomous laboratories where AI models direct the synthesis and testing of new molecules around the clock will significantly increase the speed of discovery. This will allow the industry to respond more rapidly to global health challenges, such as new viral outbreaks or the rise of antibiotic resistance. The journey is just beginning, and the potential for impact is immense.

Pharma Advancement believes that the transition to AI optimizing small molecule synthesis paths is a marathon rather than a sprint. It requires a long term commitment to data infrastructure, talent development, and organizational change. For companies that successfully navigate this transition, the rewards will be a more efficient and productive R&D engine that is well positioned for the challenges of the future. The era of data driven chemistry has arrived, and the possibilities for drug discovery are endless.

References

• IBM Research
• World Economic Forum
• Gilead Sciences
• Schrödinger
• Recursion Pharmaceuticals
• Evotec
• Merck KGaA

Streamlining Site Collaboration and Data Integrity

Using Real-World Data to Improve Clinical Study Design

At its core real world evidence involves using data collected outside of the traditional trial setting to inform and enhance the design of new studies. For example researchers can analyze existing health records to identify the specific patient subgroups that are most likely to benefit from a new therapy. This allows for a more targeted and efficient trial design where the inclusion and exclusion criteria are based on actual clinical experience rather than just theoretical assumptions. By focusing on the patients who are most likely to respond to a treatment pharmaceutical companies can improve the chances of a successful outcome and reduce the number of participants required to achieve statistical significance.

The use of external control arms is another innovative application of real world evidence. In some cases particularly for rare diseases where patient populations are extremely small it may be unethical or impractical to have a traditional placebo group. By using historical data from previous studies or current records from standard of care treatments researchers can create a virtual control group for comparison. This allows for the evaluation of a new therapy without exposing patients to a placebo. While this approach requires sophisticated statistical methods to ensure that the groups are comparable it represents a major ethical and practical advancement in the field of clinical research. Furthermore, AI has emerged as a reliable tool to help with the clinical trial planning and execution.

Strengthening Long-Term Safety Monitoring

Monitoring long term safety and effectiveness is an area where real world evidence truly shines. Traditional clinical trials are often too short to capture rare or delayed side effects that may only become apparent after a drug is used by a larger population over a longer period. By continuously analyzing real world data researchers can identify safety signals that might have been missed in the initial testing phase. This proactive approach to pharmacovigilance ensures that any potential risks are identified and addressed as quickly as possible which protects the safety of patients and maintains the integrity of the medical community.

Refining Therapeutic Value and Regulatory Strategy

The demonstration of therapeutic value is no longer just about showing that a drug works better than a placebo it is increasingly about showing how it performs relative to other available treatments. Real world evidence allows companies to conduct comparative effectiveness research using data from actual clinical practice. This information is essential for payers and health technology assessment agencies who must decide which treatments to cover and at what price. By showing that a new therapy provides superior outcomes or lower costs in the real world pharmaceutical companies can build a stronger case for the value of their products.

Supporting Regulatory Decisions and Label Expansion

Furthermore regulatory agencies are increasingly open to the use of real world evidence to support label expansions and new indications for already approved drugs. Through real world evidence sponsors can gather the necessary data without the need for additional large scale and expensive clinical trials. This allows for faster access to new treatment options for patients and more efficient use of research resources. The transition toward a more integrated and flexible regulatory framework is a vital part of the effort to modernize the drug development process and to ensure that it remains responsive to the needs of the public.

Bringing Patient Perspectives Into Clinical Evidence

The integration of patient reported outcomes into the evidence base is also enhanced through real world data. Traditional trials often focus on objective clinical measures such as lab results or imaging while failing to capture the patient perspective on their own health and well being.

By using mobile apps and digital tools to collect data on symptoms and quality of life in a real world setting researchers can gain a much deeper understanding of the impact of a disease and its treatment. This patient centric approach to real world evidence ensures that the development process is aligned with the goals and values of the people who will ultimately use the medications.

Overcoming Challenges and Ensuring Data Integrity

While the potential of real world evidence is immense its use also presents several challenges that must be addressed. The data used in real world studies is often less structured and more prone to missing information than the data collected in a controlled trial. Through real world evidence researchers must implement rigorous data cleaning and validation processes to ensure that the final evidence is reliable and accurate. The use of advanced analytics and machine learning can help in identifying and correcting these issues but human oversight remains essential for maintaining the high standards of scientific research.

Protecting Patient Data and Maintaining Trust

Data privacy and security are also paramount when working with sensitive health information. As researchers access and combine data from multiple sources they must ensure that all patient identifiers are removed and that the information is protected from unauthorized access. The commitment to ethical and secure data practices is the foundation upon which the entire field of real world evidence is built. By adhering to global privacy standards and being transparent about how data is used researchers can build trust with patients and the public and ensure the long term success of their work.

Advancing the Future of Evidence-Based Drug Development

In conclusion the integration of real world evidence into the pharmaceutical research landscape is a vital and transformative development. By bridging the gap between controlled studies and everyday practice these insights are improving the quality and relevance of medical evidence. The benefits extend from the researchers who have access to more comprehensive data to the patients who receive treatments that are better aligned with their actual needs. As we continue to refine the tools and techniques for gathering and analyzing real world data the role of evidence based medicine will only become more central to the pursuit of better health outcomes. The era of the truly informed clinical trial has begun.

Moving Toward a Hybrid Clinical Research Model

Final reflections on the topic suggest that the future of clinical research will be defined by a hybrid model that combines the strengths of traditional trials with the insights of real world evidence. This balanced approach will allow for a more efficient and responsive and patient centric drug development process. Pharma Advancement believes that by embracing the power of real world data we are setting the stage for a new generation of medical innovation that is grounded in the reality of clinical practice. The journey toward a more comprehensive understanding of health and disease is well underway and real world evidence is the compass guiding our way.

Accelerating Molecular Design and Lead Optimization

One of the most profound ways how GenAI is changing pharma sector research workflows is in the early stages of drug discovery—specifically in the design of new molecular structures. Traditionally, chemists relied on their intuition and vast libraries of existing compounds to identify potential drug leads. GenAI, particularly through models like Variational Autoencoders (VAEs) and Generative Adversarial Networks (GANs), can explore a virtually infinite chemical space to suggest entirely new molecules with specific desired properties. Instead of testing thousands of existing compounds, researchers can now use GenAI to dream up the perfect molecule designed to hit a specific biological target while minimizing potential side effects.

This transition from search and find to design and build significantly compresses the lead optimization phase. GenAI models can simultaneously optimize for multiple variables, such as binding affinity, solubility, and metabolic stability, which used to take months or years of iterative laboratory testing. By predicting how a molecule will behave before it is even synthesized, GenAI allows researchers to focus their physical resources on the most promising candidates. This specific shift in how GenAI is changing pharma sector research workflows not only saves time but also allows for the exploration of undruggable targets that have baffled scientists for generations, opening the door to treatments for rare and complex diseases.

Transforming Protein Folding and Target Identification

The impact of GenAI extends into the realm of structural biology. The breakthrough of models like AlphaFold and its successors has demonstrated how GenAI is changing pharma sector research workflows by solving the protein-folding problem—predicting the complex three-dimensional structure of a protein from its amino acid sequence. Understanding a protein’s shape is crucial for identifying where a drug can bind to it. GenAI tools can now predict these structures in minutes rather than the years of experimental work previously required using X-ray crystallography or cryo-electron microscopy.

This newfound speed in structural prediction is revolutionizing target identification. Researchers can now rapidly screen entire proteomes to identify novel binding sites for new therapies. GenAI is also being used to design de novo proteins—synthetic proteins that do not exist in nature but are engineered to perform specific therapeutic functions, such as neutralizing a virus or regulating an enzyme. This creative capability is a hallmark of how GenAI is changing pharma sector research workflows, moving the industry from discovering what exists to creating what is needed for optimal health outcomes.

Streamlining Clinical Trial Design and Operations

Beyond the lab, the clinical trial phase is where the majority of drug development costs and delays occur. GenAI is making significant inroads here, offering a smarter way to manage the complexity of human testing. One key area of how GenAI is changing pharma sector research workflows is in the creation of synthetic control arms. By utilizing vast amounts of historical trial data and real-world evidence, GenAI can generate a digital representation of a control group. This reduces the number of human participants needed for the placebo arm of a trial, which not only speeds up the process but also addresses the ethical concerns of denying treatment to patients with life-threatening conditions.

GenAI is also optimizing the writing and management of clinical trial protocols. A typical protocol is a massive document that must be meticulously drafted to ensure regulatory compliance and patient safety. GenAI models can now draft these documents, ensuring they are consistent, clear, and incorporate all necessary regulatory requirements. Furthermore, GenAI can analyze patient data in real-time to identify potential participants who are most likely to respond to a treatment or those who might be at high risk for adverse events. This precision in patient selection is a vital part of how GenAI is changing pharma sector research workflows, leading to higher success rates in Phase II and III trials.

Enhancing Data Synthesis and Regulatory Reporting

The volume of documentation in pharma is staggering. For every new drug, thousands of pages of reports must be filed with agencies like the FDA or EMA. GenAI is uniquely suited for the task of summarizing vast quantities of unstructured data, such as scientific papers, clinical notes, and patient feedback. By automating the synthesis of this information, GenAI allows regulatory affairs teams to focus on the strategic aspects of their filings rather than the administrative burden of document preparation.

Furthermore, how GenAI is changing pharma sector research workflows includes the ability to generate plain-language summaries for patients and healthcare providers. Transparency is becoming a key requirement in clinical trials, and GenAI can take complex medical data and translate it into accessible information that helps patients understand the risks and benefits of a new therapy. This democratization of information is an often-overlooked but essential benefit of the GenAI revolution in pharma, fostering greater trust between the industry and the public.

The Role of Knowledge Graphs and Cross-Disciplinary Insights

Pharma research has traditionally been siloed, with different teams focusing on biology, chemistry, and clinical science. GenAI is helping to break down these barriers by creating knowledge graphs—complex networks that connect disparate pieces of information from across the entire research spectrum. By analyzing these graphs, GenAI can identify non-obvious connections, such as a drug originally designed for hypertension that might have potential in treating a specific type of neurodegenerative disease.

This capability for cross-pollination of ideas is a major component of how GenAI is changing pharma sector research workflows. It enables a more holistic view of human biology and disease, allowing researchers to see the big picture that might be missed by a human specialist focusing on a single narrow area. As these knowledge graphs become more sophisticated and populated with multi-omic data (genomics, proteomics, metabolomics), the ability of GenAI to suggest novel therapeutic hypotheses will only grow, further accelerating the pace of medical innovation.

Ethical Considerations and Data Integrity

As the industry embraces these new tools, the question of how GenAI is changing pharma sector research workflows also brings up critical ethical and technical considerations. Ensuring the integrity of the data used to train GenAI models is paramount. If the training data is biased or incomplete, the resulting molecules or trial designs could be flawed. Pharma companies are therefore investing heavily in AI governance and explainable AI to ensure that the decisions made by these models are transparent, reproducible, and ethically sound.

There is also the challenge of intellectual property. If a GenAI model designs a new molecule, who owns the patent? Current legal frameworks are still catching up with this reality. However, the industry is moving toward a collaborative model where GenAI is seen as a co-pilot for human researchers, augmenting their creativity and expertise rather than replacing it. This human-in-the-loop approach is central to how GenAI is changing pharma sector research workflows, ensuring that the final decisions—especially those involving patient safety—remain firmly in human hands.

New Era of Personalized and Rapid Medicine

In conclusion, the impact of Generative AI on the pharmaceutical industry is nothing short of revolutionary. From the microscopic level of molecular design to the global scale of clinical trial management, how GenAI is changing pharma sector research workflows is visible at every stage of the value chain. Pharma Advancement believes that by reducing the time and cost of drug development, GenAI holds the promise of making life-saving treatments more accessible and personalized than ever before. It allows the industry to tackle diseases that were once thought untreatable and to respond with unprecedented speed to emerging health threats.

As we look to the future, the integration of GenAI into pharma will only deepen. We are moving toward a world where the research workflow is a seamless blend of human ingenuity and artificial intelligence, constantly learning and evolving. The transition is not without its challenges, particularly in regulation and ethics, but the potential benefits for human health are far too great to ignore. How GenAI is changing pharma sector research workflows is not just a trend. It is the blueprint for a new era of medical discovery that will redefine what is possible in the quest to heal and protect humanity.

The Logic and Economics of Repurposing Existing Medicines

Drug repurposing is an inherently attractive strategy for the pharmaceutical industry. The development of a brand-new drug from scratch is a high-risk venture with a high failure rate. In contrast, a repurposed drug has already undergone extensive testing for toxicity, absorption, and metabolism. This allows researchers to bypass the early stages of development and move directly into Phase II or III clinical trials for the new indication. AI strengthens drug repurposing strategies by making this search process more efficient. Instead of relying on accidental discoveries—like the famous case of sildenafil (Viagra), which was originally developed for heart disease—researchers can now use AI to proactively identify candidates for a wide range of conditions, from cancer and autoimmune disorders to rare genetic diseases.

The economic impact is substantial. By reducing the development timeline by several years and cutting costs by hundreds of millions of dollars, drug repurposing makes it financially viable to develop treatments for rare diseases or neglected tropical diseases that might not otherwise attract significant investment. AI strengthens drug repurposing strategies by lowering the barrier to entry for innovation, allowing smaller biotech companies and academic institutions to contribute to the global drug pipeline. This democratization of drug discovery is a vital part of the shift toward a more agile and responsive healthcare system.

Leveraging Knowledge Graphs and Multi-Omics Data

The core of how AI strengthens drug repurposing strategies lies in its ability to integrate and analyze massive, heterogeneous datasets. Modern AI models use knowledge graphs, complex maps that connect drugs, targets, genes, proteins, and diseases. By analyzing the topology of these graphs, AI can identify non-obvious relationships. For example, if a drug is known to inhibit a specific protein that is also involved in the pathway of a completely different disease, the AI can flag that drug as a potential candidate for repurposing. This guilt by association logic, powered by deep learning, allows for a much more comprehensive search than human researchers could ever perform manually.

Furthermore, AI strengthens drug repurposing strategies by incorporating multi-omics data. By looking at how a drug affects the entire transcriptome or proteome of a cell, AI can identify off-target effects that might be therapeutically useful for another condition. This level of granular insight allows scientists to understand the polypharmacology of a drug—the idea that a single medication can interact with multiple targets in the body. By harnessing this complexity rather than being overwhelmed by it, AI turns the pharmaceutical industry’s existing knowledge into a powerful engine for new therapeutic discovery.

Case Studies: AI Successes in Drug Repositioning

The effectiveness of AI-driven repurposing was clearly demonstrated during the COVID-19 pandemic. As the world searched for immediate treatments, AI models were used to screen thousands of existing drugs for their potential to inhibit the virus or dampen the cytokine storm associated with severe cases. AI strengthens drug repurposing strategies by providing a rapid response capability that is essential in a global health crisis. Several drugs, such as baricitinib (originally for rheumatoid arthritis), were identified as potential COVID-19 treatments through AI-led efforts and subsequently validated in clinical trials, helping to save countless lives before vaccines were widely available.

Beyond pandemics, AI strengthens drug repurposing strategies in the field of oncology. Cancer is a highly complex disease where the same tumor can be driven by multiple different genetic mutations. AI can analyze a patient’s tumor profile and suggest repurposed drugs that might hit those specific targets, often in combination with traditional therapies. This personalized approach to repurposing is also gaining ground in neurology, where drugs originally designed for diabetes or inflammation are being investigated for their potential to slow the progression of Alzheimer’s or Parkinson’s disease. The ability of AI to see patterns across completely different therapeutic areas is its most transformative feature.

Overcoming Intellectual Property and Regulatory Hurdles

While the science is promising, the path to a repurposed drug is often blocked by non-scientific barriers. One major challenge is intellectual property (IP). If a drug is already off-patent, there is little financial incentive for a pharma company to fund the expensive clinical trials needed for a new indication. AI strengthens drug repurposing strategies by identifying novel drug-disease combinations that can potentially be patented, providing the necessary protection for investment. Furthermore, AI can help identify new ways to deliver an old drug—such as a different dosage form or a targeted delivery system—which can also create new IP opportunities.

Regulatory bodies are also adapting to the rise of repurposing. Agencies like the FDA have established specific pathways (such as the 505(b)(2) pathway in the U.S.) to streamline the approval of repurposed drugs. AI strengthens drug repurposing strategies by providing the robust evidence needed to support these applications. By using real-world evidence and advanced simulations to prove the potential efficacy of a repurposed drug, AI helps build a compelling case for regulators, further speeding up the journey from the computer screen to the patient’s bedside.

The Role of Network Pharmacology and Virtual Screening

A key technical component of how AI strengthens drug repurposing strategies is virtual screening. Instead of physically testing drugs in a lab, AI models can simulate the interaction between a drug and a disease target in a virtual environment. This allows for the screening of thousands of compounds in a fraction of the time. These models are becoming increasingly sophisticated, incorporating the dynamic nature of protein structures and the complexities of the cellular environment. By narrowing down the field to the most likely candidates, AI ensures that laboratory resources are used as efficiently as possible.

Network pharmacology is another emerging field where AI strengthens drug repurposing strategies. Instead of looking for a single drug that hits a single target, network pharmacology looks at the entire biological network involved in a disease. AI can suggest combinations of repurposed drugs that hit multiple points in that network, providing a more robust and effective treatment. This cocktail approach is already a standard in HIV and cancer treatment, and AI is now helping to bring it to other complex chronic diseases, opening up a new frontier of multi-target therapy.

Ethical Considerations and Global Health Impact

The use of AI in drug repurposing also has a strong ethical dimension. Because repurposed drugs are often cheaper and easier to manufacture than new ones, they are ideal for improving health equity in low- and middle-income countries. AI strengthens drug repurposing strategies by identifying treatments for diseases that are prevalent in these regions but are often ignored by traditional drug discovery programs. This focus on socially responsible innovation is a vital part of the pharmaceutical industry’s mission to improve global health outcomes.

However, we must also be mindful of the risks. Ensuring that the data used to train AI models is representative and that the algorithms are transparent is essential for maintaining trust. AI strengthens drug repurposing strategies by acting as a tool for human discovery, not a replacement for clinical judgment. The final decision to use a repurposed drug for a new patient group must always be based on rigorous clinical evidence and ethical review, ensuring that the safety and well-being of the patient remain the primary focus.

Moving Towards A More Agile and Sustainable Drug Pipeline

In conclusion, the rise of AI-driven drug repurposing marks a significant shift in the philosophy of medical discovery. Instead of always looking for the next blockbuster molecule, we are learning to better utilize the incredible resources we already have. AI strengthens drug repurposing strategies by turning a process of chance into a process of precision, providing a faster, cheaper, and more sustainable way to develop life-saving treatments. It allows the industry to be more responsive to new threats, more inclusive of rare diseases, and more efficient in its use of global resources.

As our understanding of the human body and our computational power both continue to grow, the potential for drug repurposing will only expand. AI strengthens drug repurposing strategies by serving as the bridge between the vast library of existing pharmacology and the unmet needs of patients around the world. We are entering an era where the most effective new treatment might already be sitting on the shelf of a pharmacy, waiting for an algorithm to find it and a scientist to prove it. The future of medicine is not just about discovery. Pharma Advancment believes that the future lies in rediscovery, powered by the intelligence of the machine and the mission of the healer.

The Shift from Controlled Trials to Real-World Insights

Randomized Controlled Trials, while rigorous, have inherent limitations. They often exclude patients with complex health profiles, the elderly, or pregnant women, meaning the trial results might not fully reflect how a drug performs in the real world. Furthermore, RCTs are expensive and have a limited duration, which may not capture long-term side effects or rare adverse events. This is why AI is advancing real-world evidence in pharma. It allows researchers to study the performance of a drug across millions of patients in their natural environment over extended periods. Pharma Advancement notes that by analyzing large-scale observational data, AI can identify patterns of safety and effectiveness that would be impossible to see in a smaller, controlled cohort.

The primary challenge of RWE is that the data is often dirty—it contains missing values, inconsistent coding, and unstructured text like physician notes. Traditional statistical methods struggle with these irregularities. However, AI is advancing real-world evidence in pharma through Natural Language Processing (NLP) and advanced machine learning techniques. NLP can read through millions of clinical notes to extract symptoms, side effects, and patient outcomes that are not captured in structured data fields. Machine learning algorithms can then synthesize this information, correcting for biases and identifying non-obvious correlations between treatments and outcomes. This ability to structure and analyze vast quantities of real-world data is a game-changer for the industry.

Enhancing Post-Market Surveillance and Drug Safety

One of the most critical applications of how AI is advancing real-world evidence in pharma is in post-market surveillance, often referred to as pharmacovigilance. Once a drug is on the market, regulatory agencies and pharma companies must monitor it for any unforeseen safety issues. Historically, this relied on voluntary reporting by doctors and patients, a process that is often slow and prone to under-reporting. AI is advancing real-world evidence in pharma by proactively scanning insurance claims and electronic health records to detect early signals of adverse events. By identifying safety signals in real-time, AI allows for much faster intervention, potentially saving lives and preventing widespread health crises.

Furthermore, AI is advancing real-world evidence in pharma by helping to differentiate between true drug-related side effects and symptoms caused by a patient’s underlying condition or other medications. This precision is vital for maintaining public trust in the healthcare system. If a potential safety issue is detected, AI can help researchers quickly conduct follow-up studies using historical real-world data to confirm or refute the signal, providing a much more agile response than traditional methods. This proactive safety monitoring is a cornerstone of modern pharmaceutical governance, ensuring that patient safety remains the top priority throughout a drug’s entire lifecycle.

Personalizing Treatment Pathways and Improving Outcomes

Beyond safety, AI is advancing real-world evidence in pharma by helping clinicians understand which treatments work best for specific types of patients. Real-world data often contains information on a patient’s genomic profile, lifestyle factors, and environmental exposures. By analyzing this multi-dimensional data, AI can identify subpopulations that respond particularly well to a specific medication or those who are at high risk of treatment failure. This is the essence of precision medicine: using real-world insights to tailor the right therapy to the right patient at the right time.

For example, in the treatment of chronic conditions like diabetes or cardiovascular disease, AI is advancing real-world evidence in pharma by identifying the best sequence of medications based on a patient’s unique history. Instead of a one-size-fits-all treatment algorithm, doctors can use AI-driven insights to make more informed decisions that improve long-term health outcomes and reduce the overall cost of care. This move toward value-based healthcare is heavily dependent on the ability to prove that a treatment actually works in a real-world setting, and AI provides the analytical engine to make that proof possible.

Supporting Regulatory Submissions and Strategic Decision-Making

The value of RWE is also being recognized by regulatory bodies like the FDA and the EMA. Agencies are increasingly open to using RWE to support new drug applications, particularly for expanding the label of an existing drug to new indications or for satisfying post-marketing requirements. AI is advancing real-world evidence in pharma by providing the rigorous analytical frameworks needed to ensure that RWE studies are as reliable as traditional trials. This can significantly reduce the time and cost of getting new treatments to patients who need them, particularly in oncology and rare diseases where traditional trials are difficult to conduct.

For pharmaceutical companies, AI is advancing real-world evidence in pharma by informing strategic decisions throughout the product lifecycle. RWE can identify unmet medical needs in the population, helping companies decide which new drugs to develop. It can also provide insights into how a drug is being used in clinical practice, allowing for more effective marketing and medical education programs. By integrating RWE into their core business processes, pharma companies can become more patient-centric and data-driven, ultimately improving their competitive position in an increasingly complex and regulated global market.

Addressing Data Privacy, Ethics, and Algorithmic Bias

As with any technology that relies on large-scale personal data, the fact that AI is advancing real-world evidence in pharma brings up significant ethical and privacy concerns. Ensuring the anonymity and security of patient records is paramount. AI governance frameworks must include robust data de-identification protocols and strict access controls to prevent the misuse of sensitive information. Furthermore, there is the risk of algorithmic bias. If the real-world data used to train AI models is not representative of all ethnic and socioeconomic groups, the resulting evidence could be skewed, leading to health disparities.

To mitigate these risks, the industry is adopting Privacy-Enhancing Technologies (PETs) like federated learning, which allows AI models to be trained on data located in different hospitals without the data ever having to leave its original location. This protects patient privacy while still allowing for large-scale analysis. AI is advancing real-world evidence in pharma by driving the development of these secure technologies, ensuring that the transition to data-driven medicine is both ethical and inclusive. Transparency in how AI models are built and validated is also essential for building trust with patients and regulators, making explainable AI a key requirement for the future of RWE.

A Continuous Feedback Loop of Medical Knowledge

Looking forward, the potential for RWE to transform healthcare is limited only by our ability to capture and analyze data. Pharma Advancement believes that as more health data becomes digitized, including data from social media, environmental sensors, and genomics, the richness of real-world evidence will continue to grow. AI is advancing real-world evidence in pharma by creating a continuous feedback loop between clinical research and clinical practice. Insights from the real world will inform the design of future trials, and data from those trials will be validated and refined in the real world.

This seamless integration of data will lead to a more dynamic and responsive healthcare system. We are moving toward a future where every patient’s journey contributes to a global body of knowledge, helping to improve the care of the next patient. AI is advancing real-world evidence in pharma as the essential catalyst for this transformation, turning the vast and complex landscape of real-world data into a powerful engine for medical innovation and improved human health. The era of the learning healthcare system is finally here, and it is being built on the foundation of AI-driven real-world evidence.

The Foundations of Trustworthy AI in Healthcare

In the context of life sciences, trust is the currency of the realm. Patients, healthcare providers, and regulatory bodies must have absolute confidence that a new medication is safe and effective. When AI is involved in the development process, that trust must be extended to the algorithms themselves. This is how AI governance establishes the rules of engagement for how models are built and deployed. At its core, trustworthy AI governance focuses on four main pillars: data integrity, algorithmic transparency, ethical alignment, and accountability. Without these pillars, the industry risks a black box scenario where decisions are made without a clear, auditable trail, potentially leading to catastrophic errors or biases in drug development.

Data integrity is perhaps the most fundamental aspect of governance. AI is only as good as the data it is trained on. In pharma, this data often includes sensitive patient information, complex genomic sequences, and decades of clinical trial results. AI governance can ensure that this data is accurate, representative, and collected in a way that respects patient privacy and consent. It also involves rigorous checks for bias; if an AI model is trained on data that primarily represents a single demographic, the resulting drugs or diagnostic tools may not perform as well for other populations. Governance frameworks mandate that data diversity and quality are prioritized from the very beginning of the development lifecycle.

Algorithmic Transparency and Explainability

One of the biggest hurdles to AI adoption in highly regulated sectors is the black box problem—the inability to explain exactly how an AI arrived at a specific conclusion. For a chemist or a clinical researcher, simply being told that a molecule is a good candidate is not enough; they need to understand the underlying logic.  It pushes for the development of Explainable AI (XAI), where the models are designed to provide insights into their decision-making process. This transparency is not just a technical requirement; it is a regulatory one. Agencies like the FDA are increasingly requiring that AI-driven decisions are backed by evidence that a human expert can review and validate.

Furthermore, transparency in governance involves clear documentation of the model’s limitations. An AI model that is excellent at predicting protein folding might be completely unsuited for predicting drug-drug interactions in a clinical setting. AI governance can ensure that every tool is used within its intended scope and that its performance is constantly monitored for model drift, where the AI’s accuracy degrades over time as new data is introduced. By maintaining a rigorous audit trail of a model’s performance and decision-making logic, pharma companies can demonstrate compliance and build long-term confidence with both regulators and the public.

Navigating a Shifting Regulatory Landscape

The regulatory environment for AI in pharma is currently in a state of rapid flux. From the European Union’s AI Act to the FDA’s evolving guidance on AI/ML-based software as a medical device, the legal requirements for pharmaceutical companies are becoming more defined and more stringent. A robust governance framework allows a company to adapt quickly to new rules without disrupting its research and development pipeline. It involves regular risk assessments, third-party audits, and the appointment of dedicated AI ethics and compliance officers who bridge the gap between technical teams and legal departments.

For pharma companies, non-compliance is not just a matter of fines; it can result in the rejection of a drug application, the loss of intellectual property rights, or significant reputational damage. By proactively implementing comprehensive governance, companies can position themselves as leaders in responsible innovation. This proactive stance is a vital strategic advantage. In a market where multiple companies might be using similar AI tools, the one that can prove its tools are the most reliable and ethically sound will be the one that wins the trust of payers and providers. Thus, AI governance is necessary not just for risk mitigation, but as a core component of brand value and market access.

The Ethics of AI in Drug Discovery and Trials

Beyond technical and regulatory concerns, there is a profound ethical dimension to the use of AI in life sciences. Decisions about which diseases to research, how to select patients for clinical trials, and how to price AI-derived medications all have significant social implications. AI governance becomes critical for broader societal values and human rights. This includes addressing the digital divide, where the benefits of AI-driven medicine might only be accessible to wealthy nations or individuals. Governance frameworks often include ethical charters that commit the organization to using AI in a way that promotes equity and global health.

In clinical trials, the use of AI to create synthetic control arms or to monitor patients via wearable devices raises new questions about informed consent and the right to be forgotten in digital datasets. AI governance can help ensuring that patients are fully aware of how their data is being used and that their rights are protected even in an increasingly automated environment. By fostering a culture of ethical AI, pharma companies can avoid the pitfalls of technology for technology’s sake and keep the focus where it belongs: on the well-being of the patient.

Accountability and the Human-in-the-Loop Model

A central tenet of modern AI governance is the concept that a human must always remain in the loop, especially for high-stakes decisions. While an AI can suggest a new molecular lead or identify a potential safety risk, the final responsibility for acting on that information lies with a qualified human professional. It ensures that researchers are not just blindly following an algorithm’s output but are using it as an advanced decision-support tool. This hybrid approach leverages the speed and scale of AI while maintaining the judgment, empathy, and ethical reasoning of human experts.

This human-centric governance model also involves significant investment in training and education. For AI governance to be effective, every employee—from the data scientist to the CEO—must have a baseline level of AI literacy. They need to understand the potential benefits and the inherent risks of the tools they are using. When everyone understands their role in the governance process, the system becomes more resilient and more capable of catching errors before they lead to real-world consequences.

AI Governance as a Dynamic System

The field of artificial intelligence is moving so fast that a static set of rules will quickly become obsolete. Therefore, the most effective forms of AI governance are dynamic and iterative. They involve continuous feedback loops where the performance of AI systems in the real world is used to refine the governance policies themselves. AI governance becomes critical for pharma as a living system that evolves alongside the technology. This might involve the use of AI to govern AI, where specialized oversight algorithms monitor the behavior of primary models for anomalies or bias in real-time.

As we look to the future, the integration of AI in pharma will only increase, potentially leading to fully autonomous discovery labs and hyper-personalized medicine tailored to an individual’s unique genetic code. In this future, the stakes will be even higher, and the role of governance will be even more foundational. Pharma Advancement believes that by building a robust governance architecture today, the pharmaceutical industry is preparing itself for the challenges and opportunities of tomorrow. AI governance could serve as the bridge that connects the power of the machine with the mission of the medicine, ensuring that the next generation of therapies is as safe, ethical, and effective as it is innovative.

Rasonque is administered as a tablet once daily and works by targeting multiple forms of a protein called RAS. The protein is a key driver of tumor growth in most patients with pancreatic adenocarcinoma, a cancer that develops from cells lining the ducts of the pancreas. The approval covers adults with metastatic pancreatic cancer in the form of pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” said Acting FDA Commissioner Kyle Diamantas, J.D.

“I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality,” he added.

Clinical Trial Shows Survival Benefit

Pancreatic adenocarcinoma represents approximately 90% to 95% of the 67,000 new cases of pancreatic cancer diagnosed in the United States each year, according to the National Cancer Institute. Although pancreatic adenocarcinoma makes up roughly 3.2% of all cancer diagnoses, it contributes a disproportionately high share of cancer deaths. The source attributes that burden to the disease’s typically late detection, aggressive course and historically limited treatment options.

Evidence supporting Rasonque came from a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. In the study, Rasonque increased median overall survival to 13.2 months, compared with 6.7 months for standard chemotherapy.

“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.

“The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,” he added.

Rasonque Receives Multiple FDA Designations

The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, while the treatment also received Priority Review for this indication. The application underwent an additional review through the Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the review of therapies addressing national public health priorities.

In May 2026, the FDA issued a “safe to proceed” letter allowing the sponsor to begin an expanded access treatment protocol for Rasonque. This enabled patient access to the investigational drug before approval under applicable FDA regulations.